Sigma-Aldrich (SIAL) to Acquire BioReliance Holdings in $350M Deal
Up)
Sigma-Aldrich Corporation (Nasdaq: SIAL), has signed an agreement to acquire BioReliance Holdings, Inc., a leading provider of global biopharmaceutical testing services, from Avista Capital Partners for $350 million in cash. The acquisition is subject to customary closing conditions, including regulatory clearance, and is expected to close in the first quarter of 2012.
Sigma-Aldrich expects to fund the acquisition with a combination of existing cash and credit facilities.
Morgan Stanley & Co. LLC acted as financial advisor and Bryan Cave LLP served as legal advisor to Sigma-Aldrich for this transaction.
Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!
Sigma-Aldrich expects to fund the acquisition with a combination of existing cash and credit facilities.
Morgan Stanley & Co. LLC acted as financial advisor and Bryan Cave LLP served as legal advisor to Sigma-Aldrich for this transaction.
Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!
You May Also Be Interested In
- UPDATE: SAP's (SAP) America Unit to Buy Ariba (ARBA) for $45/Share
- Dollar Thrifty (DTG) Shares Spike Higher as Hertz (HTZ) Could Make an Offer
- NBCUniversal in Talks to Buy MSNBC.com
Create E-mail Alert Related Categories
Mergers and AcquisitionsRelated Entities
Morgan StanleySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
